Relay Therapeutics insider plans 30,000-share stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics insider Sekar Kathiresan filed a notice to sell company stock. The filing covers a proposed sale of 30,000 shares of common stock of Relay Therapeutics through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $594,414.00, expected on July 21, 2026. The shares are tied to a stock option exercise by the issuer for cash. The filing also reports that, during the past three months, 66,055 shares of common stock were sold on July 20, 2026 for total proceeds of $1,293,555.07.
Key Figures
Key Terms
stock option exercise financial
Executive Financial Services financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock sale is disclosed for Relay Therapeutics (RLAY) in this Form 144?
Who is the selling security holder in the Relay Therapeutics (RLAY) Form 144 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.